Aliases & Classifications for Arteriosclerosis

MalaCards integrated aliases for Arteriosclerosis:

Name: Arteriosclerosis 12 54 6 44 15 17 71
Arteriosclerotic Vascular Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2349
MeSH 44 D001161
NCIt 50 C34398
SNOMED-CT 67 195251000
ICD10 32 I70
UMLS 71 C0003850

Summaries for Arteriosclerosis

Disease Ontology : 12 An artery disease that is characterized by a thickening and hardening of arterial walls in the arteries.

MalaCards based summary : Arteriosclerosis, also known as arteriosclerotic vascular disease, is related to arteriosclerosis obliterans and coronary heart disease 1, and has symptoms including angina pectoris An important gene associated with Arteriosclerosis is HS3ST1 (Heparan Sulfate-Glucosamine 3-Sulfotransferase 1), and among its related pathways/superpathways are Degradation of the extracellular matrix and Folate Metabolism. The drugs Progesterone and Estradiol have been mentioned in the context of this disorder. Affiliated tissues include endothelial, smooth muscle and kidney, and related phenotypes are cardiovascular system and cellular

Wikipedia : 74 Arteriosclerosis is the thickening, hardening, and loss of elasticity of the walls of arteries. This... more...

Related Diseases for Arteriosclerosis

Diseases in the Arteriosclerosis family:

Arteriosclerosis, Severe Juvenile

Diseases related to Arteriosclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 501)
# Related Disease Score Top Affiliating Genes
1 arteriosclerosis obliterans 33.2 VCAM1 MIR21 ICAM1 HGF ADIPOQ
2 coronary heart disease 1 32.2 SERPINE1 PON1 HMGCR APOB APOA1 ADIPOQ
3 pseudoxanthoma elasticum 32.1 SPP1 MGP ICAM1 ELN
4 hyperlipoproteinemia, type iii 32.1 HMGCR APOB APOA1
5 atherosclerosis susceptibility 32.0 VCAM1 SERPINE1 PPARG PON1 MGP ICAM1
6 angina pectoris 31.4 ICAM1 EDN1 APOA1 ADIPOQ
7 peripheral vascular disease 31.3 VCAM1 SERPINE1 HMGCR CCL2 APOB APOA1
8 hypertriglyceridemia, familial 31.3 SERPINE1 APOB APOA1
9 buerger disease 31.2 VCAM1 PON1 ICAM1 EDN1
10 lipid metabolism disorder 31.1 SERPINE1 PPARG PON1 MIR126 HMGCR CCL2
11 cerebrovascular disease 31.1 VCAM1 SPP1 SERPINE1 PON1 MIR21 ICAM1
12 homocysteinemia 31.1 VCAM1 SERPINE1 PON1 ELN CCL2
13 lipoprotein quantitative trait locus 31.1 VCAM1 SERPINE1 PPARG PON1 MIR21 MIR126
14 limb ischemia 31.1 SERPINE1 MIR21 ICAM1 HGF EDN1 CCL2
15 end stage renal disease 31.0 SPP1 PON1 MGP ICAM1 CCL2 APOB
16 fatty liver disease 31.0 SERPINE1 PPARG APOB ADIPOQ
17 coronary stenosis 30.9 SERPINE1 PON1 MIR21 ICAM1 APOB APOA1
18 hyperglycemia 30.9 VCAM1 SERPINE1 PPARG APOB ADIPOQ
19 carotid stenosis 30.9 VCAM1 SPP1 ICAM1 ADIPOQ
20 vascular disease 30.9 VCAM1 SPP1 SERPINE1 PPARG PON1 MIR21
21 ischemia 30.8 PON1 MIR21 ICAM1 HMOX1 HGF EDN1
22 familial hypercholesterolemia 30.8 VCAM1 SERPINE1 PON1 HMGCR APOB APOA1
23 arteries, anomalies of 30.8 VCAM1 SERPINE1 MIR21 MIR126 ICAM1 EDN1
24 takayasu arteritis 30.8 VCAM1 ICAM1 EDN1
25 pulmonary hypertension 30.8 SPP1 SERPINE1 PPARG MIR21 MIR126 HMOX1
26 hyperinsulinism 30.8 SERPINE1 PPARG EDN1 APOB ADIPOQ
27 aortic aneurysm, familial abdominal, 1 30.7 VCAM1 SPP1 SERPINE1 MIR126 ICAM1 ELN
28 peripheral artery disease 30.7 VCAM1 ICAM1 HMOX1 HGF EDN1 CCL2
29 intermediate coronary syndrome 30.7 VCAM1 MIR126 APOB APOA1
30 hypertension, essential 30.6 VCAM1 SPP1 SERPINE1 PPARG PON1 MIR21
31 uremia 30.6 SPP1 PON1 MGP
32 glomerulonephritis 30.6 VCAM1 SPP1 ICAM1 CCL2
33 chronic kidney disease 30.6 VCAM1 SPP1 SERPINE1 PPARG PON1 MIR21
34 proteasome-associated autoinflammatory syndrome 1 30.6 VCAM1 PPARG ICAM1 CCL2 ADIPOQ
35 cerebral aneurysms 30.6 HMOX1 ELN
36 systemic lupus erythematosus 30.6 VCAM1 SPP1 SERPINE1 PON1 MIR21 ICAM1
37 carotid artery disease 30.6 PON1 MIR126 CCL2 APOB APOA1
38 non-alcoholic fatty liver disease 30.5 SPP1 SERPINE1 PPARG MIR21 MIR126 HMOX1
39 aortic atherosclerosis 30.5 SPP1 PON1 ADIPOQ
40 kidney disease 30.5 VCAM1 SPP1 SERPINE1 PPARG PON1 MIR21
41 connective tissue disease 30.5 SPP1 MIR21 MIR126 ELN EDN1 CCL2
42 non-alcoholic steatohepatitis 30.4 SERPINE1 PPARG MIR21 HGF CCL2 ADIPOQ
43 hyperlipidemia, familial combined, 3 30.4 PON1 HMGCR APOB APOA1 ADIPOQ
44 iga glomerulonephritis 30.4 SPP1 ICAM1 CCL2
45 retinal vascular disease 30.4 MIR21 MIR126 ICAM1 CCL2
46 sleep apnea 30.4 VCAM1 SERPINE1 ICAM1 EDN1 CCL2 APOB
47 type 2 diabetes mellitus 30.4 VCAM1 SPP1 SERPINE1 PPARG PON1 MIR126
48 osteoporosis 30.4 SPP1 SERPINE1 PPARG MIR21 MGP ICAM1
49 diabetes mellitus 30.3 VCAM1 SPP1 SERPINE1 PPARG PON1 MIR126
50 apnea, obstructive sleep 30.3 SERPINE1 ICAM1 EDN1 ADIPOQ

Graphical network of the top 20 diseases related to Arteriosclerosis:



Diseases related to Arteriosclerosis

Symptoms & Phenotypes for Arteriosclerosis

UMLS symptoms related to Arteriosclerosis:


angina pectoris

MGI Mouse Phenotypes related to Arteriosclerosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.18 ADIPOQ APOA1 APOB EDN1 HGF HMOX1
2 cellular MP:0005384 10.13 ADIPOQ APOA1 APOB DAB2IP HGF HMGCR
3 growth/size/body region MP:0005378 10.07 ADIPOQ APOB EDN1 HGF HMGCR HMOX1
4 homeostasis/metabolism MP:0005376 10.03 ADIPOQ APOA1 APOB DAB2IP EDN1 HMGCR
5 liver/biliary system MP:0005370 9.61 ADIPOQ APOA1 APOB HGF HMGCR HMOX1
6 muscle MP:0005369 9.23 ADIPOQ APOB EDN1 HMOX1 ICAM1 MGP

Drugs & Therapeutics for Arteriosclerosis

Drugs for Arteriosclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 236)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
2
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
3
Polyestradiol phosphate Approved Phase 4 28014-46-2
4
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
5
Remifentanil Approved Phase 4 132875-61-7 60815
6
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
7
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
8
Atenolol Approved Phase 4 29122-68-7 2249
9
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
10
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
11
Propranolol Approved, Investigational Phase 4 525-66-6 4946
12
Heparin Approved, Investigational Phase 4 9005-49-6 772 9812414
13
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
14
Pravastatin Approved Phase 4 81093-37-0 54687
15
Dipyridamole Approved Phase 4 58-32-2 3108
16
Acetaminophen Approved Phase 4 103-90-2 1983
17
Metformin Approved Phase 4 657-24-9 14219 4091
18
Sevelamer Approved Phase 4 52757-95-6
19
Calcium acetate Approved, Investigational Phase 4 62-54-4
20
Ezetimibe Approved Phase 4 163222-33-1 150311
21
Zinc Approved, Investigational Phase 4 7440-66-6 32051
22
Alendronate Approved Phase 4 121268-17-5, 66376-36-1 2088
23
Insulin detemir Approved Phase 4 169148-63-4 5311023
24
Insulin aspart Approved Phase 4 116094-23-6 16132418
25
Probucol Approved, Investigational Phase 4 23288-49-5 4912
26
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
27
Atorvastatin Approved Phase 4 134523-00-5 60823
28
tannic acid Approved Phase 4 1401-55-4
29
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
30
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
31
Evolocumab Approved Phase 4 1256937-27-5
32
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
33
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
34
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
35
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
36
Mycophenolic acid Approved Phase 4 24280-93-1 446541
37
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
38
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
39
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
40 Beraprost Investigational Phase 4 88430-50-6
41 Prasugrel hydrochloride Phase 4 389574-19-0
42 Estradiol 17 beta-cypionate Phase 4
43 Estradiol 3-benzoate Phase 4
44 Cyclooxygenase 2 Inhibitors Phase 4
45 Hypnotics and Sedatives Phase 4
46 Narcotics Phase 4
47 Analgesics, Opioid Phase 4
48 Anesthetics, Intravenous Phase 4
49 Anesthetics, General Phase 4
50 Anesthetics, Inhalation Phase 4

Interventional clinical trials:

(show top 50) (show all 312)
# Name Status NCT ID Phase Drugs
1 Evaluation of Antiplatelet Therapy in Lower Limb Endovascular Treatment Unknown status NCT00912756 Phase 4 cilostazol
2 The Low HDL On Six Weeks Statin Therapy (LOW) Study Unknown status NCT00238004 Phase 4 Nicotinic acid
3 Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI) Unknown status NCT01777503 Phase 4 prasugrel;Clopidogrel
4 A Randomised, Placebo Controlled, Double Blind, Cross-over, Single Center Clinical Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4 Ivabradine;Placebo
5 Effects of Estrogen Replacement on Atherosclerosis Progression in Recently Menopausal Women Unknown status NCT00154180 Phase 4 Conjugated equine estrogens 0.45 mg/day;Transdermal estradiol, 50 mcg/day;Micronized progesterone, 200 mg/day x 12 d/month;CEE , progesterone, estradiol patch or placebo for each;CEE, progesterone, transdermal patch or the placebo
6 Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis - High-Resolution Magnetic Resonance Imaging Study (STAMINA-MRI Study) Unknown status NCT02458755 Phase 4 High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg
7 A Pilot Study to Determine the Effect of Celecoxib on Markers of Inflammation in Patients With Hypertension and Coronary Artery Disease Completed NCT00471341 Phase 4 Celecoxib;placebo
8 Comparison of Intravenous Anesthetics and Volatile Anesthetics on Postoperative Cognitive Dysfunction of Patients Undergoing Endovascular Repair of Aortic Aneurysm and Endovascular Treatment of Arteriosclerosis Obliterans of Lower Extremities. Completed NCT02107170 Phase 4 Sevoflurane;Propofol;Remifentanil
9 Reducing Total Cardiovascular Risk in an Urban Community Completed NCT00241904 Phase 4 Antiplatelet Agents;Beta Blocker;ACE Inhibitors
10 A Randomized, Control,Open Label, Multicentre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker Completed NCT00823849 Phase 4 Cilostazol;Probucol;Cilostazol+Probucol
11 Prospective, Randomized Trial of Drug-eluting Stents vs. Bare Metal Stents for the Reduction of Restenosis in Bypass Grafts. Completed NCT00611910 Phase 4
12 ACTFAST: Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration. A Multicenter, Twelve-Week Treatment, Single Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With Atorvastatin Starting Doses Of 10 Mg, 20 Mg, 40 Mg, And 80 Mg Completed NCT00442845 Phase 4 Atorvastatin (Lipitor)
13 A Prospective, Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Atorvastatin Versus Pravastatin on the Progression and Quantification of Coronary Atherosclerotic Lesions as Measured by Intravascular Ultrasound (REVERSAL) Completed NCT00380939 Phase 4 Atorvastatin;Pravastatin
14 A Multicenter, Randomized Double-Blind Study Comparing The Pleiotropic Effects Of Atorvastatin 10 Mg And 80 Mg Over A 26-Week Period In Subjects With Coronary Atherosclerosis Completed NCT00163202 Phase 4 Atorvastatin
15 Graft Patency Outcomes in Patients Undergoing Coronary Artery Bypass Grafting Via Minimally Invasive Coronary Surgery Completed NCT01334866 Phase 4
16 ACTFAST (2): Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration: A Multicenter, Twelve-Week Treatment, Single-Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With Atorvastatin Starting Doses Of 10 mg, 20 mg, 40 mg, And 80 mg. Completed NCT00442325 Phase 4 Atorvastatin (Lipitor)
17 A Prospective, Randomized, Multicenter Comparison of the Drug-Eluting Stent Systems YUKON Choice and TAXUS Liberté in Patients With Diabetes Mellitus Completed NCT00368953 Phase 4
18 Effects of Celecoxib on Restenosis After Percutaneous Coronary Intervention and Evolution of Atherosclerosis (COREA) Trial Completed NCT00292721 Phase 4 Celecoxib
19 Preprocedural Asprin Reload for Native Coronary Disease Treated by Angioplasty: Reperfusion Indexes Evaluation and Improvement of Clinical Outcome -PANTAREI Study Completed NCT01374698 Phase 4 Aspirin
20 The Ontario Multidetector Computed Tomography (MDCT) Coronary Angiography Study (OMCAS) Completed NCT00371891 Phase 4
21 A Randomised, Crossover Study Comparing the Biochemical and Platelet Effects of Modified-release Dipyridamole/Aspirin (200mg/25 mg bd; Asasantin Retard®) With Aspirin (75 mg qd) in Coronary Artery Disease Patients With Aspirin Resistance Manifesting as Persistent Thromboxane Formation. Completed NCT00129038 Phase 4 modified-release dipyridamole/aspirin;aspirin
22 Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial Completed NCT02510547 Phase 4
23 Paracetamol and Endothelial Function in Patients With Stable Coronary Artery Disease Completed NCT00534651 Phase 4 Paracetamol
24 Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Completed NCT00110448 Phase 4 Aspirin;No aspirin
25 Capturing Outcomes of Clinical Activities Performed by a Rounding Pharmacist Practising in a Team Environment (COLLABORATE) Completed NCT00351676 Phase 4 Optimizing therapeutic treatments
26 CARE-2 (Calcium Acetate (PhosLo®)/Sevelamer(Renagel®) Evaluation Study 2) Completed NCT00211939 Phase 4 calcium acetate;sevelamer;atorvastatin
27 A Single Center, Randomized, Parallel Groups, Placebo-Controlled Study Comparing The Efficacy, Safety, And Tolerability Of The Daily Co-administration Of Ezetimibe 10 Mg Or Ezetimibe Placebo To Ongoing Treatment With Atorvastatin 10 Mg In Subjects With Primary Hypercholesterolemia And Multiple Coronary Heart Disease Risk Factors in Indonesian Population. Completed NCT00319449 Phase 4 Ezetimibe;Placebo;Atorvastatin 10 mg
28 Pilot Study: Inflammation and Coronary Artery Disease. Role of AT1 Receptor Antagonism Completed NCT00274144 Phase 4 telmisartan 40 mg;placebo 40 mg
29 A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions Completed NCT01182428 Phase 4
30 Randomised Controlled Trial of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease: A Pilot Study Completed NCT00395382 Phase 4 Alendronate;Placebo
31 Prospective, Randomized, Comparative Study to Evaluate the Effect of Iodixanol 320 Compared to Iomeprol 350 on Contrast Medium Induced Nephropathy in Patients With Impaired Renal Function Undergoing PCI Completed NCT00390585 Phase 4 Iodixanol 320;Iomeprol 350
32 ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial Completed NCT00161070 Phase 4 anticoagulation;aspirin and dipyridamole;aspirin alone
33 The Effect of Metformin Versus Placebo, Including Three Insulin-Analogue Regimens With Variating Postprandial Glucose Regulation, on CIMT in T2DM Patients - A Randomized, Multicenter Trial Completed NCT00657943 Phase 4 metformin;insulin detemir;insulin aspart + insulin aspart protamin;Insulin aspart
34 A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions Completed NCT00496938 Phase 4
35 Multicenter Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Efficacy and Safety of Divaza in the Management of Oxidative Disturbances in Cerebral Atherosclerosis Completed NCT03485495 Phase 4 Divaza;Placebo
36 A Randomized, Control, Open Label, Multicentre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject Completed NCT00823875 Phase 4 Cilostazol group;Probucol group;Cilostazol + Probucol group;control group
37 Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD): A Prospective, Multicenter, Randomized, Controlled Trial Recruiting NCT04624854 Phase 4 Clopidogrel and Aspirin dual-antiplatelet therapy;Aspirin monotherapy
38 Effects of Melatonin on Progression of Coronary Artery Calcification Recruiting NCT03966235 Phase 4 Melatonin 3 mg;Placebo
39 The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques: a Prospective, Random, Single-center Study Based on High Resolution Magnetic Resonance Imaging Recruiting NCT03753555 Phase 4 Atorvastatin Calcium;Atorvastatin Calcium;Probucol
40 Reducing Intracranial atheroSclErosis With Repatha Not yet recruiting NCT04573777 Phase 4 Repatha
41 Randomised Comparison of Two Different Immunosuppressive Regimens on Progression of Arteriosclerosis in Renal Transplant Patients. Terminated NCT01276834 Phase 4 everolimus
42 Combination of Beraprost Sodium Tablets (Dorner) and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients Terminated NCT02786979 Phase 4 Beraprost;Aspirin
43 EARly Prevention of aTHeroma Progression Terminated NCT02105623 Phase 4 Rosuvastatin
44 Randomized-controlled Trial of a Combined vs. Conventional Percutaneous Intervention for Near-Infrared Spectroscopy Defined High-Risk Native Coronary Artery Lesions Terminated NCT02601664 Phase 4
45 A Double Blind, 2:1 Randomised Monocentre Study to Investigate the Efficacy and Safety of Telmisartan (80 mg qd) Concerning the Amelioration of Structural Alterations and Function of Endothelium in Cardiovascular Risk Patients (SAFE-CRP: Structural Alterations and Function of Endothelium in Cardiovascular Risk Patients) Terminated NCT00274105 Phase 4 telmisartan;Placebo
46 Multicenter Clinical Trial for Development of Guidelines of Adequate Blood Pressure Lowering in the Subacute Ischemic Stroke Patients Due to Intracranial Atherosclerosis Terminated NCT01104311 Phase 4
47 Study of Urinary Kallikrein to Enhance Collateral Circulation in Symptomatic Intracranial Atherosclerosis: a Study Based on Whole-brain CTP Withdrawn NCT04325932 Phase 4 Urinary Kallikrein
48 The Effectiveness of Ranolazine in Reducing Cardiac Ischaemia Induced by Chronic Total Occlusions of Coronary Arteries Withdrawn NCT02423265 Phase 4 Ranolazine;Placebo
49 Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Extended Registry Withdrawn NCT02974777 Phase 4 DAPT reduction;DAPT on-target;DAPT intensification
50 Does Omega-3 Polyunsaturated Fatty Acids (PUFAs) Pretreatment Improve Outcomes in Patients Undergoing Percutaneous Coronary Intervention (PCI)? Unknown status NCT01723345 Phase 3 omega 3

Search NIH Clinical Center for Arteriosclerosis

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Epoprostenol
Epoprostenol Sodium
Isoxsuprine
Isoxsuprine Hydrochloride

Cochrane evidence based reviews: arteriosclerosis

Genetic Tests for Arteriosclerosis

Anatomical Context for Arteriosclerosis

MalaCards organs/tissues related to Arteriosclerosis:

40
Endothelial, Smooth Muscle, Kidney, Heart, Skin, Bone Marrow, Eye

Publications for Arteriosclerosis

Articles related to Arteriosclerosis:

(show top 50) (show all 11867)
# Title Authors PMID Year
1
HS3ST1 genotype regulates antithrombin's inflammomodulatory tone and associates with atherosclerosis. 6
28126521 2017
2
Decrease in glomerular filtration rate by plasma low-density lipoprotein cholesterol in subjects with normal kidney function assessed by urinalysis and plasma creatinine. 54 61
20097344 2010
3
Aldosterone antisecretagogue and antihypertensive actions of adrenomedullin in patients with primary aldosteronism. 61 54
20150911 2010
4
Paraoxonase-1 gene haplotypes are associated with metabolic disturbances, atherosclerosis, and immunologic outcome in HIV-infected patients. 61 54
20078196 2010
5
Wild-type apo A-I and apo A-I(Milano) gene transfer reduce native and transplant arteriosclerosis to a similar extent. 54 61
19066833 2009
6
Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells. 54 61
19132220 2008
7
Relationships of adiponectin and matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio with coronary plaque morphology in patients with acute coronary syndrome. 61 54
18464944 2008
8
Analysis of plasma adipocytokines related to clinical and laboratory data in the maintenance hemodialysis patients. 61 54
18670142 2008
9
Influence of serum high-molecular-weight and total adiponectin on arteriosclerosis in IgA nephropathy patients. 54 61
18332637 2008
10
[Endothelin-1 production and its involvement in cardiovascular diseases]. 61 54
17827914 2007
11
[Pioglitazone protects against elastocalcinosis and improves aortic wall elasticity]. 54 61
17489075 2007
12
General anesthesia and methylenetetrahydrofolate reductase deficiency. 54 61
18008117 2007
13
[Effects of recombinant adenovirus encoding human apM1 gene on proliferation and nitric oxide synthase activity in human umbilical vein endothelial cells]. 61 54
17274908 2006
14
Endothelial-mediated regulation of cerebral microcirculation. 54 61
17244945 2006
15
Upregulation of proteinase-activated receptors and hypercontractile responses precede development of arterial lesions after balloon injury. 61 54
16844909 2006
16
Pathophysiologic and therapeutic implications of adrenomedullin in cardiovascular disorders. 61 54
16616959 2006
17
Protective genes in the vessel wall: Modulators of graft survival and function. 61 54
16829794 2006
18
TGF-beta1 generates a specific multicomponent extracellular matrix in human coronary SMC. 61 54
16796604 2006
19
Signaling and functions of angiopoietin-1 in vascular protection. 61 54
16645151 2006
20
Recent advances in the relationship between obesity, inflammation, and insulin resistance. 61 54
16613757 2006
21
[Effects of active components extracted from Qixue Bingzhi Recipe on proliferation of vascular smooth muscle cells and expressions of platelet-derived growth factor and its receptor genes]. 54 61
16409966 2006
22
Adrenomedullin: a protective factor for blood vessels. 54 61
16141406 2005
23
Tempol attenuates the development of hypertensive renal injury in Dahl salt-sensitive rats. 54 61
15882555 2005
24
Matrix Gla protein and osteopontin genetic associations with coronary artery calcification and bone density: the CARDIA study. 54 61
15744522 2005
25
Endothelial nitric oxide synthase gene transfer restores endothelium-dependent relaxations and attenuates lesion formation in carotid arteries in apolipoprotein E-deficient mice. 61 54
15578196 2005
26
Increased plasma lipid-poor apolipoprotein A-I in patients with coronary artery disease. 54 61
15550473 2005
27
[Endothelin-1 and arteriosclerosis]. 61 54
15506470 2004
28
CD14 C(-260)T gene polymorphism, circulating soluble CD14 levels and arteriosclerosis. 54 61
15257175 2004
29
Eukaryotic expression vector of heme oxygenase-1 and its expression in endothelial cell. 54 61
15313669 2004
30
Inhibition of accelerated graft arteriosclerosis by gene transfer of soluble fibroblast growth factor receptor-1 in rat aortic transplants. 54 61
15072997 2004
31
[The antioxidant function of high density lipoproteins: a new paradigm in atherosclerosis]. 54 61
15225502 2004
32
Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. 61 54
15181084 2004
33
Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site. 54 61
14963043 2004
34
A microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with increased bilirubin and HDL levels but not with coronary artery disease. 54 61
14691581 2004
35
Attenuation of aortic graft arteriosclerosis by systemic administration of Allotrap peptide RDP58. 54 61
12942166 2003
36
Effect of low-density lipoprotein apheresis on plasma endothelin-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans. 54 61
14583180 2003
37
[Neurological aspects in antiphospholipid syndrome]. 54 61
15152454 2003
38
Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury. 61 54
14581407 2003
39
[Regulatory effect of yishou tiaozhi tablet on lipids in patients with primary hyperlipidemia]. 61 54
12764909 2003
40
Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. 61 54
12628953 2003
41
Mouse endothelial CD40 expression does not play a role during the development of transplant arteriosclerosis. 54 61
12791519 2003
42
The concentration of lipids, lipoproteins and apolipoproteins in cord blood serum of newborns in the course of intrauterine period. 61 54
15323161 2003
43
Antiinflammatory and antiarteriosclerotic effects of pioglitazone. 54 61
12411463 2002
44
Upregulation of PAI-1 is mediated through TGF-beta/Smad pathway in transplant arteriopathy. 61 54
12231371 2002
45
Hepatocyte growth factor and 24-hour ambulatory blood pressure monitoring. 61 54
12452315 2002
46
Levels of haemostatic factors, arteriosclerosis and cardiovascular disease. 61 54
12616975 2002
47
Gene therapy targeting monocyte chemoattractant protein-1 for vascular disease. 54 61
12560586 2002
48
A survey of the dietary nutritional composition of centenarians. 61 54
11677774 2001
49
[Effect of lower androgen levels on arteriosclerosis]. 61 54
11769606 2001
50
Chromosomal location, exon structure, and vascular expression patterns of the human PDGFC and PDGFD genes. 54 61
11342471 2001

Variations for Arteriosclerosis

ClinVar genetic disease variations for Arteriosclerosis:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 HS3ST1 NM_005114.3(HS3ST1):c.-108-6848A>G SNV risk factor 441163 rs16881446 4:11408585-11408585 4:11406961-11406961

Expression for Arteriosclerosis

Search GEO for disease gene expression data for Arteriosclerosis.

Pathways for Arteriosclerosis

GO Terms for Arteriosclerosis

Cellular components related to Arteriosclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 10.02 VCAM1 SPP1 SERPINE1 PON1 MIR21 MGP
2 extracellular region GO:0005576 9.9 SPP1 SERPINE1 PON1 MGP HGF ELN
3 extracellular space GO:0005615 9.47 VCAM1 SPP1 SERPINE1 PON1 MIR21 MIR126
4 low-density lipoprotein particle GO:0034362 9.46 APOB APOA1
5 chylomicron GO:0042627 9.43 APOB APOA1
6 high-density lipoprotein particle GO:0034364 9.43 PON1 APOB APOA1
7 collagen-containing extracellular matrix GO:0062023 9.43 SERPINE1 MGP ICAM1 ELN APOA1 ADIPOQ
8 spherical high-density lipoprotein particle GO:0034366 9.4 PON1 APOA1
9 intermediate-density lipoprotein particle GO:0034363 9.32 APOB APOA1

Biological processes related to Arteriosclerosis according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Name GO ID Score Top Affiliating Genes
1 angiogenesis GO:0001525 9.99 SERPINE1 HMOX1 DAB2IP CCL2
2 cytokine-mediated signaling pathway GO:0019221 9.99 VCAM1 ICAM1 HMOX1 HGF CCL2
3 response to lipopolysaccharide GO:0032496 9.95 VCAM1 ICAM1 EDN1 APOB
4 extracellular matrix organization GO:0030198 9.95 VCAM1 SPP1 SERPINE1 ICAM1 ELN
5 negative regulation of cell migration GO:0030336 9.93 SERPINE1 MIR21 MIR126 ADIPOQ
6 cellular response to hypoxia GO:0071456 9.9 MIR126 ICAM1 HMOX1 EDN1
7 cholesterol homeostasis GO:0042632 9.89 HMGCR APOB APOA1
8 cellular response to interferon-gamma GO:0071346 9.89 ICAM1 EDN1 CCL2
9 positive regulation of inflammatory response GO:0050729 9.88 SERPINE1 MIR21 MIR126
10 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.88 ICAM1 HGF ADIPOQ
11 regulation of lipid metabolic process GO:0019216 9.88 PPARG HMGCR APOA1
12 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.88 MIR21 MIR126 HGF
13 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.88 MIR21 MIR126 ICAM1 HMGCR CCL2
14 response to organic substance GO:0010033 9.87 SPP1 PPARG APOB
15 cell chemotaxis GO:0060326 9.87 VCAM1 HGF CCL2
16 response to ethanol GO:0045471 9.87 VCAM1 ICAM1 HMGCR ADIPOQ
17 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.86 MIR21 DAB2IP ADIPOQ
18 response to nutrient levels GO:0031667 9.85 PON1 HMGCR ADIPOQ
19 regulation of blood pressure GO:0008217 9.84 PPARG HMOX1 EDN1
20 cholesterol metabolic process GO:0008203 9.84 PON1 HMGCR APOB APOA1
21 response to estrogen GO:0043627 9.83 PPARG HMOX1 APOA1
22 positive regulation of smooth muscle cell proliferation GO:0048661 9.83 HMOX1 HMGCR EDN1
23 response to hypoxia GO:0001666 9.83 VCAM1 ICAM1 HMOX1 EDN1 ADIPOQ
24 animal organ regeneration GO:0031100 9.81 PPARG HGF APOA1
25 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.8 PPARG HMOX1 ADIPOQ
26 cellular response to lipopolysaccharide GO:0071222 9.8 SERPINE1 MIR21 ICAM1 DAB2IP CCL2
27 response to drug GO:0042493 9.8 PPARG ICAM1 HMOX1 EDN1 APOA1 ADIPOQ
28 negative regulation of MAP kinase activity GO:0043407 9.79 HMGCR DAB2IP ADIPOQ
29 negative regulation of endothelial cell apoptotic process GO:2000352 9.78 SERPINE1 MIR126 ICAM1
30 positive regulation of angiogenesis GO:0045766 9.77 SERPINE1 MIR21 MIR126 HMOX1 HGF
31 cellular response to interleukin-1 GO:0071347 9.76 ICAM1 EDN1 DAB2IP CCL2
32 response to nicotine GO:0035094 9.75 VCAM1 HMOX1 EDN1
33 negative regulation of vascular endothelial cell proliferation GO:1905563 9.73 PPARG MIR126 CCL2
34 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.72 MIR21 ICAM1
35 lipoprotein transport GO:0042953 9.72 PPARG APOB
36 negative regulation of blood coagulation GO:0030195 9.71 SERPINE1 EDN1
37 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.7 PPARG ADIPOQ
38 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.7 MIR21 MIR126 HMOX1
39 chylomicron assembly GO:0034378 9.69 APOB APOA1
40 low-density lipoprotein particle clearance GO:0034383 9.69 HMOX1 APOB ADIPOQ
41 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.68 APOA1 ADIPOQ
42 negative regulation of hormone secretion GO:0046888 9.68 EDN1 ADIPOQ
43 regulation of p38MAPK cascade GO:1900744 9.67 HGF DAB2IP
44 negative regulation of smooth muscle cell apoptotic process GO:0034392 9.67 MIR21 EDN1
45 chylomicron remodeling GO:0034371 9.67 APOB APOA1
46 positive regulation of cholesterol efflux GO:0010875 9.67 PON1 APOA1 ADIPOQ
47 positive regulation of fatty acid metabolic process GO:0045923 9.65 PPARG ADIPOQ
48 negative regulation of inflammatory response GO:0050728 9.65 PPARG MIR126 HGF APOA1 ADIPOQ
49 lipoprotein biosynthetic process GO:0042158 9.64 APOB APOA1
50 membrane to membrane docking GO:0022614 9.64 VCAM1 ICAM1

Molecular functions related to Arteriosclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 SPP1 EDN1 CCL2 ADIPOQ
2 signaling receptor binding GO:0005102 9.02 SERPINE1 EDN1 CCL2 APOA1 ADIPOQ

Sources for Arteriosclerosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....